Title: Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization study

Short title: GLP-1R and mental health

Authors:

Guoyi Yang, PhD[a,b*], Stephen Burgess, PhD[c,d], C Mary Schooling, PhD[a,e]

[a] School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

[b] Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

[c] MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

[d] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

[e] Graduate School of Public Health and Health Policy, City University of New York, New York, USA

[*]**Corresponding author: Guoyi Yang, PhD**

Postal address: 1/F, Patrick Manson Building, 7 Sassoon Road, Pokfulam, Hong Kong

Email address: yanggy@connect.hku.hk

Telephone: +852 98147624

ORCID: 0000-0002-4387-386X

Word count: 2984

The number of tables: 0

The number of figures: 4

Abstract

Concerns have been raised about the psychiatric safety of glucagon-like peptide-1 receptor (GLP-1R) agonists, but trial evidence suggests that they ameliorate depressive symptoms. We aimed to assess the associations of GLP-1R activation with mental health well-being and the risk of mental health disorders and substance use disorders. We performed drug-target Mendelian randomization and colocalization analyses using the largest relevant publicly available genome-wide association studies in European ancestry individuals. After correcting for multiple comparisons, genetically predicted lower body mass index (BMI) via GLP-1R activation was associated with a better well-being spectrum (0.06 standard deviation [95% confidence interval 0.03-0.08]) and lower risk of depression (odds ratio 0.83 [0.74-0.94]) and bipolar disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m^2 decrease in BMI. There was also suggestive evidence that genetically predicted lower BMI via GLP-1R activation was associated with lower risk of post-partum depression, attention deficit hyperactivity disorder, and substance use disorders, and that genetically predicted lower glycated hemoglobin (HbA1c) via GLP-1R activation was associated with higher risk of anorexia nervosa but lower risk of Tourette syndrome. These associations were stronger than the associations for genetically predicted lower BMI and lower HbA1c based on genome-wide variants. The posterior probabilities of a shared causal variant affecting both BMI and the outcome at the *GLP1R* gene were 59.3% for the well-being spectrum, 3.8% for depression, and 45.9% for bipolar

disorder. GLP-1R activation was associated with better mental health well-being and lower risk of depression and bipolar disorder beyond that expected from the reduction in BMI and HbA1c.

(Word count: 250)

Keywords: bipolar disorder, depression, glucagon-like peptide-1 receptor, Mendelian randomization, mental health

Introduction

Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce body weight and blood glucose.[1] Randomized controlled trials (RCTs) have shown cardiovascular and mortality benefits of GLP-1R agonists.[2,3] GLP-1R agonists act on the hindbrain, the hypothalamus, and vagal afferents to suppress food intake and reduce body weight.[4-6] Anti-obesity drugs affecting central nervous systems could have psychiatric effects. For example, the combination of phentermine and topiramate increases depression and anxiety.[7] Rimonabant was withdrawn from the market due to serious psychiatric adverse effects.[8] In contrast, the combination of naltrexone and bupropion improves depression,[9] smoking cessation,[10,11] and methamphetamine use disorder.[12]

Following reports of suicidal ideation and self-injury in people using GLP-1R agonists,[13] the European Medicines Agency and the US Food and Drug Administration have been monitoring the psychiatric safety of GLP-1R agonists. To date, the available evidence does not suggest a causal association of GLP-1R agonist use with suicidal thoughts and actions.[14,15] RCTs have suggested that GLP-1R agonists moderately reduce depressive symptoms in people who are overweight or obese[16] and in people with type 2 diabetes.[17] Animal studies[18,19] and observational studies[20,21] suggest potential benefits of GLP-1R agonists in alcohol use disorder, but evidence from RCTs is lacking.[22] Early-stage trials are on-going to investigate the efficacy of GLP-1R agonists in individuals with mental illnesses[23] and substance use

disorders.[24] A better understanding of the association of GLP-1R activation, the intended target of GLP-1R agonists, with mental health has implications for informing their psychiatric safety and potential repurposing opportunities.

Mendelian randomization (MR), an instrumental variable analysis with genetic instrument, is less confounded than conventional observational studies.[25] Previous MR studies suggested no association of GLP-1R activation with suicide risk,[26,27] consistent with an RCT.[16] We used MR to assess the associations of GLP-1R activation with mental health outcomes including the well-being spectrum, mental health disorders, and substance use disorders. We further investigated whether any associations were explained by lowering body mass index (BMI) or lowering glycated hemoglobin (HbA1c).

Subjects and methods

Ethical approval of studies and informed consent

All the analyses were conducted using publicly available summary statistics, which does not require ethical approval.

Study design

MR relies on the instrumental variable assumptions of relevance (the genetic

instruments should be related to the exposure), independence (no common cause of the genetic instruments and the outcome exists), and exclusion restriction (the genetic instruments should be independent of the outcome given the exposure).[28] This MR study took advantage of the largest relevant publicly available genome-wide association studies (GWASs) (eTable 1). First, we assessed the associations of GLP-1R activation predicted by *GLP1R* variants with mental health outcomes including the well-being spectrum, mental health disorders, and substance use disorders. We compared these associations with the associations for lower BMI and lower HbA1c predicted by genome-wide variants. Second, we performed colocalization analyses to examine whether any associations found for GLP-1R activation were driven by a shared causal variant affecting both BMI or HbA1c and the outcome at the *GLP1R* gene.[29] Where possible, we conducted sex-specific analyses, because women are more likely to have depression than men,[30] but boys are more likely to develop neurodevelopmental disorders than girls.[31]

Genetic instruments

We selected genetic instruments for GLP-1R activation based on their associations with BMI (N = 806,834) from a meta-analysis of the UK Biobank and GIANT[32] and with HbA1c (N = 344,182) from a GWAS of the UK Biobank.[33] We considered these two sets of instruments separately, because they might represent distinct mechanisms.[34] To mimic BMI-related mechanisms, we extracted variants in or near

118 (+- 1Mb) the *GLP1R* gene that were uncorrelated (r^2<0.001) and genome-wide
119 significantly (*p* value <5×10^{-8}) associated with BMI. To mimic HbA1c-related
120 mechanisms, we used the same approach based on their associations with HbA1c. We
121 also extracted genetic instruments for BMI and HbA1c from across the genome
122 (genome-wide variants) that were uncorrelated (r^2 <0.001) and genome-wide
123 significantly (*p* value <5×10^{-8}) associated with BMI and HbA1c, respectively.
124
125 We used coronary artery disease (CAD) and all-cause mortality as positive control
126 outcomes, because RCTs have shown that GLP-1R agonists reduce cardiovascular
127 events and death.[2,3] We obtained genetic associations with CAD (181,522
128 cases/984,168 controls) from a meta-analysis of the CARDIoGRAMplusC4D
129 consortium and the UK Biobank.[35] We obtained genetic associations with parental
130 mortality (609,139 cases/403,101 controls) from a meta-analysis of the UK Biobank
131 and LifeGen as a measure of all-cause mortality,[36] because it has more power than
132 participant's mortality.
133
134 ***Genetic associations with mental health outcomes***
135 We obtained sex-combined and sex-specific genetic associations with mental health
136 outcomes from the largest relevant publicly available GWASs.[33,37-51] Primary
137 outcomes included the well-being spectrum, mental health disorders (depression,
138 bipolar disorder, post-traumatic stress disorder (PTSD), schizophrenia, anorexia

nervosa, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder, and Tourette's syndrome), and substance use disorders. Secondary outcomes included four dimensions of mental health well-being (life satisfaction, positive affect, neuroticism, and depressive symptoms) and subtypes of mental health disorders (postpartum depression and bipolar disorder I and II) and substance use disorders (cannabis use disorder and alcohol dependence). Secondary outcomes also included the Alcohol Use Disorders Identification Test (AUDIT) total score, score for alcohol consumption, and score for alcohol problems. Genetic associations with binary outcomes obtained using linear regression were transformed into odds ratio (OR) using an established approximation.[52]

MR analysis

We used the F-statistic to assess instrument strength, approximated by the square of SNP-exposure association divided by the square of its standard error.[53] An F-statistic larger than 10 suggests weak instrument bias is unlikely. We aligned SNPs on the same allele for exposure and outcome, and used proxy SNPs (r^2>0.8), where possible, when SNPs were not available in the outcome GWAS. We calculated Wald estimates by dividing genetic association with outcome by genetic association with exposure. We obtained MR estimates by meta-analyzing Wald estimates using inverse variance weighting (IVW) with fixed effects for three SNPs or fewer and random effects for four SNPs or more.[54] To assess the robustness of IVW estimates, we conducted

sensitivity analyses using the weighted median[55] and MR Egger.[56] The MR Egger intercept assesses directional pleiotropy.[56] We used a Bonferroni corrected significance level of $\alpha=0.05/10=0.005$ given ten primary outcomes. We considered nominally significant associations (p value <0.05) that did not reach Bonferroni corrected significance as suggestive evidence. We tested differences by sex using a two-sided z-test.[57]

Colocalization

We performed colocalization analyses in a Bayesian framework to assess whether any associations found for GLP-1R activation were driven by a shared causal variant affecting both BMI or HbA1c and the outcome or were confounded by linkage disequilibrium.[29] We assessed the posterior probability of several hypotheses, including H_0 (no association with either trait), H_1, (association with BMI or HbA1c only); H_2, (association with the outcome only); H_3, (associations of two independent variants and one for each trait); H_4 (associations of one shared variant with both traits).[29] A posterior probability of H_4 larger than 0.80 suggests colocalization.[29] The power to detect colocalization is low when the variants are not strongly associated with the outcome,[58] so we also calculated the posterior probability of H_4 conditional on the presence of a variant associated with the outcome ($H_2 + H_3 + H_4$). We included variants (minor allele frequency >0.1%) in or near (+- 1Mb) the *GLP1R* gene. We set the prior probabilities as recommended, that is 10^{-4} for a variant associated with BMI

or HbA1c, 10^{-4} for a variant associated with the outcome, and 10^{-5} for a variant associated with both traits.[29] All statistical analyses were conducted using R version 4.2.1 and the packages "ieugwasr", "TwoSampleMR", "MendelianRandomization", "metafor", and "coloc".

Results

Genetic instruments

To genetically predict lower BMI via GLP-1R activation, we obtained two *GLP1R* SNPs (rs17757975 and rs4714290) based on their associations with BMI (eTable 2). To genetically predict lower HbA1c via GLP-1R activation, we obtained one *GLP1R* SNP (rs10305518) based on its association with HbA1c (eTable 2). The *GLP1R* SNPs for BMI were not associated with HbA1c and vice versa (eTable 3), which substantiated that they represent distinct mechanisms.[34] We also extracted 516 (overall), 303 (women), and 256 (men) SNPs for BMI and 318 (overall), 200 (women), 174 (men) SNPs for HbA1c from across the genome (eTable 4). The F-statistics were all >10 (eTables 2 and 4).

In positive control analyses, genetically predicted lower BMI and lower HbA1c via GLP-1R activation were associated with lower CAD risk and all-cause mortality, despite wide confidence intervals (CIs) (eFigure 1). The point estimates suggested

similar or stronger associations for genetically predicted GLP-1R activation than for genetically predicted lower BMI and lower HbA1c based on genome-wide variants (eFigure 1 and eTable 5).

Associations of GLP-1R activation with mental health well-being

Genetically predicted lower BMI via GLP-1R activation was associated with a better well-being spectrum, including life satisfaction, positive affect, neuroticism, and depressive symptoms (Figure 1). The associations with depressive symptoms were similar in women and men (eFigure 2). These associations were stronger than the associations for genetically predicted lower BMI using genome-wide variants (Figure 1 and eTables 6-7). However, genetically predicted lower HbA1c via GLP-1R activation had little association with mental health well-being (Figure 1).

Associations of GLP-1R activation with the risk of mental health disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of depression, postpartum depression, bipolar disorder, bipolar disorder I and II, and ADHD (Figure 2). The association with depression was possibly stronger in women (OR (95% CI) 0.75 (0.52 to 1.08)) than men (0.98 (0.65 to 1.47)), although the *p* value for sex difference was 0.35 (eFigure 3). These associations were stronger than the associations for genetically predicted lower BMI using genome-wide variants

(Figure 2 and eTable 8). Genetically predicted lower HbA1c via GLP-1R activation was associated with higher risk of anorexia nervosa but lower risk of Tourette syndrome, with stronger associations than the associations for genetically predicted lower HbA1c using genome-wide variants (Figure 2 and eTable 8).

Associations of GLP-1R activation with the risk of substance use disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of substance use disorders and lower AUDIT score for alcohol problems, with stronger associations than the associations for genetically predicted lower BMI using genome-wide variants (Figure 3 and eTable 9). However, genetically predicted lower HbA1c via GLP-1R activation had little association with the risk of substance use disorders (Figure 3).

Colocalization

After correcting for multiple comparisons, genetically predicted lower BMI via GLP-1R activation remained significantly associated with the well-being spectrum, life satisfaction, positive affect, neuroticism, depressive symptoms, depression, bipolar disorder, and bipolar disorder I (p values <0.005). Colocalization analyses were performed for BMI and each significant outcome in or near (+- 1Mb) the *GLP1R* gene. The posterior probabilities of a shared causal variant associated with both traits

were <80% for all the significant outcomes, but they were >80% when conditioning on the presence of a variant associated with the outcome except for depression (Figure 4). The posterior probabilities of two independent variants associated with each trait were <15% for all the significant outcomes (eTable 10). Conditioning on the presence of a shared causal variant associated with both traits, rs4714290, rs847784 (a proxy for rs4714290, $r^2 = 0.89$), or rs17757975 had the largest probability of being the shared variant.

Discussion

Consistent with RCTs,[16,17] this MR study suggests that GLP-1R activation is associated with lower risk of depression. We build on the evidence base by showing that GLP-1R activation is associated with a better well-being spectrum and lower risk of bipolar disorder. We also provide suggestive evidence that GLP-1R activation is associated with lower risk of postpartum depression, ADHD, Tourette syndrome, and substance use disorders but higher risk of anorexia nervosa. These associations were stronger than those expected from the reduction in BMI and HbA1c.

Our investigations suggest that GLP-1R activation is associated with a better well-being spectrum and lower risk of depression and bipolar disorder. Consistently, RCTs have shown that GLP-1R agonists moderately reduce depression symptoms in

overweight people[16] and in people with type 2 diabetes.[17] A small open-label trial showed that liraglutide improved cognitive function[59] and brain volumes[60] in people with depression or bipolar disorder. GLP-1 has neuroprotective effects including enhanced neurogenesis, improved barrier function, reduced neuroinflammation, and decreased oxidative stress.[61] These effects might contribute to the psychiatric benefits of GLP-1R activation and are consistent with RCTs showing that GLP-1R agonists improve neurodegenerative diseases, such as Parkinson's disease.[62,63]

Interestingly, the associations of GLP-1R activation with mental health well-being, depression, and bipolar disorder were evident when instrumenting on BMI but not on HbA1c, suggesting the relevance of BMI-related mechanisms. A recent study showed that GLP-1R agonists target the hindbrain dorsal vagal complex to decrease food intake and body weight.[4] Actions on the hypothalamus and vagal afferents also contribute to the weight loss on GLP-1R agonists.[5,6] GLP neurons in the dorsal vagal complex moderate stress responses and stimulate hypothalamic-pituitary-adrenal (HPA) axis activity, which has been implicated in the pathology of depression[64] and bipolar disorder.[65] Notably, the HPA axis is also related to cognitive function,[64,65] consistent with an RCT showing that dulaglutide reduces cognitive impairment in people with type 2 diabetes.[66] Additional studies are warranted to elucidate the mechanisms underlying potential benefits of GLP-1R agonists for mental health.

We found that GLP-1R activation was possibly associated with lower risk of depression more in women than men and was associated with lower risk of postpartum depression. Women are about twice as likely as men to have depression during their lifetime with the difference starting at puberty.[30] A meta-analysis of RCTs showed that GLP-1R agonists decreased testosterone and increased sex hormone-binding globulin in women with polycystic ovary syndrome,[67] but their effects on estrogen are less clear. Sex hormones might contribute to GLP-1R activation improving depression in women, given their potential roles in modulating serotonergic neurotransmission, cortisol, and oxytocin.[68]

GLP-1R activation was not associated with higher risk of neurodevelopmental disorders including ADHD, autism spectrum disorder, and Tourette syndrome. RCTs have showed the short-term (no more than 26 weeks) safety of GLP-1R agonists in children and adolescents.[69] We add to the evidence by suggesting that lifelong GLP-1R activation is not associated with adverse effects on neurodevelopmental disorders, which usually take a longer period of time to develop and have been less considered in RCTs. However, GLP-1R activation was possibly associated with higher risk of anorexia nervosa when instrumenting on HbA1c. GLP-1R activation increases insulin secretion and sensitivity and lowers glucose.[70] A previous MR study suggested an inverse association of fasting insulin with the risk of anorexia nervosa,[71] indicating a role of insulin sensitivity.

We provide suggestive evidence that GLP-1R activation is associated with lower risk of substance use disorders and lower AUDIT score for alcohol problems. This finding is consistent with animal studies[18,19] and observational studies[20,21] showing potential benefits of GLP-1R agonists for alcohol use disorder. However, the only RCT including people with alcohol use disorder showed that 26 weeks of treatment with exenatide did not significantly reduce heavy drinking days, although exenatide attenuated fMRI alcohol cue reactivity in brain areas for drug reward and addiction.[22] More evidence from RCTs is needed to determine the repurposing opportunities of GLP-1R agonists for treating substance use disorders.

The associations of GLP-1R activation with mental health outcomes were stronger than those expected from lowering BMI and HbA1c. Correspondingly, RCTs have showed that semaglutide reduces cardiovascular events and mortality more than expected from the reduction in body weight,[16] and that GLP-1R agonists outperform other anti-diabetes drugs.[72] Apart from reducing body weight and glucose, GLP-1R agonists also decrease blood pressure, low-density lipoprotein cholesterol, and inflammation and enhance kidney function.[2,3] We extend the evidence by suggesting that GLP-1R activation is associated with better mental health beyond that expected from the reduction in BMI and HbA1c, which may also contribute to the cardiovascular and mortality benefits of GLP-1R agonists.[73] A parsimonious model

324 explaining the multifaceted effects of GLP-1R agonists would be helpful. For
325 example, GLP-1R agonists activating AMP-activated protein kinase (AMPK)[74] can
326 explain several aspects of their benefits, given the central role of AMPK in
327 metabolism across tissues including the brain.[75]
328
329 This is the first drug-target MR study comprehensively exploring the associations of
330 GLP-1R activation with mental health outcomes. The finding that GLP-1R activation
331 is associated with better mental health well-being and lower risk of bipolar disorder is
332 novel. Our investigation also has implications for the use of GLP-1R agonists in
333 people with mental health disorders, who usually have higher risk of obesity and type
334 2 diabetes but are undertreated. This study has several limitations. First, MR relies on
335 three rigorous assumptions, that is genetic instruments should be related to the
336 exposure, share no common cause with the outcome, and be independent of the
337 outcome given the exposure.[28] The F-statistics were >10, suggesting minimal weak
338 instrument bias. We validated the genetic instruments using CAD and all-cause
339 mortality as positive control outcomes. Second, we selected genetic instruments for
340 GLP-1R activation based on their associations with BMI and HbA1c, but additional
341 underlying factors may explain their psychiatric effects. Instrumenting on BMI and
342 HbA1c could have masked some effects of GLP-1R activation. Third, the power to
343 detect colocalization was insufficient. However, the posterior probabilities of two
344 independent variants associated with each trait were <15% for all the significant

outcomes, suggesting that the associations found were unlikely driven by confounding due to linkage disequilibrium. Fourth, MR can be open to selection bias from selecting on genetic makeup and mental health disorders. Nevertheless, such selection should bias towards a harmful effect of GLP-1R activation, which does not explain its associations with lower risk of depression and bipolar disorder. Fifth, mental health disorders sometimes originate during childhood or adolescence, but GLP-1R agonists are primarily used in adults. MR assesses lifelong effects of GLP-1R activation on mental health, which cannot directly inform the quantitative short-term effects of GLP-1R agonists. RCTs are warranted to determine the clinical relevance of these findings in the future.

Conclusions

This drug-target MR study provides genetic evidence that GLP-1R activation is associated with better mental health well-being and lower risk of depression and bipolar disorder beyond that expected from the reduction in BMI and HbA1c.

Acknowledgements

The authors acknowledge Pulit SL, et al., the Neale lab, the CARDIoGRAMplusC4D Consortium, Timmers PR, et al., Baselmans BML, et al., and the Psychiatric

Genomics Consortium for their publicly available summary data.

Funding

SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). The funders had no role in the study design, analyses, or interpretation of results.

Conflict of interest

The authors declared no conflict of interest.

Data availability

Summary statistics analyzed are available in the website https://doi.org/10.5281/zenodo.1251813 for BMI, http://www.nealelab.is/uk-biobank/ for HbA1c, https://www.cardiogramplusc4d.org/data-downloads/ for CAD, https://www.ebi.ac.uk/gwas/publications/30642433 for parental mortality, https://www.ebi.ac.uk/gwas/publications/30643256 for mental health well-being, https://pgc.unc.edu/for-researchers/download-results/ for mental health disorders and substance use disorders.

Contribution statement

GY and CMS designed the study. GY undertook analyses with feedback from SB and CMS. GY drafted the manuscript with critical feedback and revisions from SB and CMS. All authors read and approved the final version of the manuscript. GY had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Artificial intelligence (AI)-assisted technologies

The authors declared that AI-assisted technologies were not used in this study.

References

1 Andersen, A., Lund, A., Knop, F. K. & Vilsbøll, T. Glucagon-like peptide 1 in health and disease. *Nature reviews. Endocrinology* **14**, 390-403, doi:10.1038/s41574-018-0016-2 (2018).

2 Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S. *et al.* Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *The New England journal of medicine* **389**, 2221-2232, doi:10.1056/NEJMoa2307563 (2023).

3 Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S. *et al.* Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *The lancet. Diabetes & endocrinology* **9**, 653-662, doi:10.1016/s2213-8587(21)00203-5 (2021).

4 Huang, K. P., Acosta, A. A., Ghidewon, M. Y., McKnight, A. D., Almeida, M. S., Nyema, N. T. *et al.* Dissociable hindbrain GLP1R circuits for satiety and aversion. *Nature*, doi:10.1038/s41586-024-07685-6 (2024).

5 Burmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J. *et al.* The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice. *Diabetes* **66**, 372-384, doi:10.2337/db16-1102 (2017).

6 Krieger, J. P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W. & Lee, S. J. Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. *Diabetes* **65**, 34-43, doi:10.2337/db15-0973 (2016).

7 Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L. *et al.* Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet (London, England)* **377**, 1341-1352, doi:10.1016/s0140-6736(11)60205-5 (2011).

8 Topol, E. J., Bousser, M. G., Fox, K. A., Creager, M. A., Despres, J. P., Easton, J. D. *et al.* Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet (London, England)* **376**, 517-523, doi:10.1016/s0140-6736(10)60935-x (2010).

9 Pi-Sunyer, X., Apovian, C. M., McElroy, S. L., Dunayevich, E., Acevedo, L. M. & Greenway, F. L. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. *International journal of obesity (2005)* **43**, 2085-2094, doi:10.1038/s41366-018-0302-z (2019).

10 Hurt, R. D., Sachs, D. P., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C. *et al.* A comparison of sustained-release bupropion and placebo for

439 smoking cessation. *The New England journal of medicine* **337**, 1195-1202,
440 doi:10.1056/nejm199710233371703 (1997).
441 11 Mooney, M. E., Schmitz, J. M., Allen, S., Grabowski, J., Pentel, P., Oliver, A.
442 *et al.* Bupropion and naltrexone for smoking cessation: A double-blind
443 randomized placebo-controlled clinical trial. *Clinical pharmacology and*
444 *therapeutics* **100**, 344-352, doi:10.1002/cpt.402 (2016).
445 12 Trivedi, M. H., Walker, R., Ling, W., Dela Cruz, A., Sharma, G., Carmody, T.
446 *et al.* Bupropion and Naltrexone in Methamphetamine Use Disorder. *The New*
447 *England journal of medicine* **384**, 140-153, doi:10.1056/NEJMoa2020214
448 (2021).
449 13 *European Medicines Agency. EMA statement on ongoing review of GLP-1*
450 *receptor agonists*, <https://www.ema.europa.eu/en/news/ema-statement-
451 ongoing-review-glp-1-receptor-agonists> (2023).
452 14 *European Medicines Agency. Meeting highlights from the Pharmacovigilance*
453 *Risk Assessment Committee (PRAC) 8-11 April 2024.*,
454 <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-
455 risk-assessment-committee-prac-8-11-april-2024> (2024).
456 15 *US Food and Drug Administration. Update on FDA's ongoing evaluation of*
457 *reports of suicidal thoughts or actions in patients taking a certain type of*
458 *medicines approved for type 2 diabetes and obesity.*,
459 <https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-

evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type> (2024).

16 Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F. *et al.* Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. *JAMA internal medicine*, doi:10.1001/jamainternmed.2024.4346 (2024).

17 Chen, X., Zhao, P., Wang, W., Guo, L. & Pan, Q. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry* **32**, 117-127, doi:10.1016/j.jagp.2023.08.010 (2024).

18 Suchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C., Momenan, R. *et al.* The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. *Translational psychiatry* **5**, e583, doi:10.1038/tp.2015.68 (2015).

19 Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S. *et al.* Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. *EBioMedicine* **93**, 104642, doi:10.1016/j.ebiom.2023.104642 (2023).

20 Wium-Andersen, I. K., Wium-Andersen, M. K., Fink-Jensen, A., Rungby, J., Jørgensen, M. B. & Osler, M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. *Basic & clinical pharmacology & toxicology* **131**, 372-379, doi:10.1111/bcpt.13776 (2022).

21 Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C. & Xu, R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. *Nature communications* **15**, 4548, doi:10.1038/s41467-024-48780-6 (2024).

22 Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A., Zeeman, V. A. *et al.* Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. *JCI insight* **7**, doi:10.1172/jci.insight.159863 (2022).

23 Ganeshalingam, A. A., Uhrenholt, N. G., Arnfred, S., Gæde, P. H., Bilenberg, N. & Frystyk, J. Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial. *BMJ open* **14**, e077173, doi:10.1136/bmjopen-2023-077173 (2024).

24 Köhne, S., Hillemacher, T., Glahn, A. & Bach, P. Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. *Expert opinion on emerging drugs* **29**, 219-232, doi:10.1080/14728214.2024.2342951

(2024).

25 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Statistics in medicine* **27**, 1133-1163, doi:10.1002/sim.3034 (2008).

26 Zhao, S. S., Burgess, S. & Gill, D. Glucagon-Like Peptide-1 Receptor Agonism and Suicide Risk: Evidence From Mendelian Randomization. *Journal of the American Heart Association* **13**, e035948, doi:10.1161/jaha.124.035948 (2024).

27 Nguyen, A., Smith, E., Hashemy, H., Agarwal, S. M., Hahn, M. K., Paterson, A. D. *et al.* Glucagon-like-peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association. *Clinical obesity* **14**, e12676, doi:10.1111/cob.12676 (2024).

28 Didelez, V. & Sheehan, N. Mendelian randomization as an instrumental variable approach to causal inference. *Statistical methods in medical research* **16**, 309-330, doi:10.1177/0962280206077743 (2007).

29 Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS genetics* **10**, e1004383, doi:10.1371/journal.pgen.1004383 (2014).

30 Kuehner, C. Why is depression more common among women than among

men? *The lancet. Psychiatry* **4**, 146-158, doi:10.1016/s2215-0366(16)30263-2 (2017).

31 Bölte, S., Neufeld, J., Marschik, P. B., Williams, Z. J., Gallagher, L. & Lai, M. C. Sex and gender in neurodevelopmental conditions. *Nature reviews. Neurology* **19**, 136-159, doi:10.1038/s41582-023-00774-6 (2023).

32 Locke, A. E., Kahali, B., Berndt, S. I., Justice, A. E., Pers, T. H., Day, F. R. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206, doi:10.1038/nature14177 (2015).

33 *UK Biobank (Neale lab). http://www.nealelab.is/uk-biobank/.*

34 Patel, A., Gill, D., Shungin, D., Mantzoros, C. S., Knudsen, L. B., Bowden, J. *et al.* Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis-multivariable Mendelian randomization to GLP1R gene region. *Genetic epidemiology* **48**, 151-163, doi:10.1002/gepi.22551 (2024).

35 Aragam, K. G., Jiang, T., Goel, A., Kanoni, S., Wolford, B. N., Atri, D. S. *et al.* Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nature genetics* **54**, 1803-1815, doi:10.1038/s41588-022-01233-6 (2022).

36 Timmers, P. R., Mounier, N., Lall, K., Fischer, K., Ning, Z., Feng, X. *et al.* Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances. *eLife* **8**,

doi:10.7554/eLife.39856 (2019).

37 Baselmans, B. M. L., Jansen, R., Ip, H. F., van Dongen, J., Abdellaoui, A., van de Weijer, M. P. *et al.* Multivariate genome-wide analyses of the well-being spectrum. *Nature genetics* **51**, 445-451, doi:10.1038/s41588-018-0320-8 (2019).

38 Howard, D. M., Adams, M. J., Clarke, T. K., Hafferty, J. D., Gibson, J., Shirali, M. *et al.* Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nature neuroscience* **22**, 343-352, doi:10.1038/s41593-018-0326-7 (2019).

39 Guintivano, J., Byrne, E. M., Kiewa, J., Yao, S., Bauer, A. E., Aberg, K. A. *et al.* Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression. *The American journal of psychiatry* **180**, 884-895, doi:10.1176/appi.ajp.20230053 (2023).

40 Mullins, N., Forstner, A. J., O'Connell, K. S., Coombes, B., Coleman, J. R. I., Qiao, Z. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nature genetics* **53**, 817-829, doi:10.1038/s41588-021-00857-4 (2021).

41 Nievergelt, C. M., Maihofer, A. X., Klengel, T., Atkinson, E. G., Chen, C. Y., Choi, K. W. *et al.* International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci.

Nature communications **10**, 4558, doi:10.1038/s41467-019-12576-w (2019).

42 Trubetskoy, V., Pardiñas, A. F., Qi, T., Panagiotaropoulou, G., Awasthi, S., Bigdeli, T. B. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* **604**, 502-508, doi:10.1038/s41586-022-04434-5 (2022).

43 Watson, H. J., Yilmaz, Z., Thornton, L. M., Hübel, C., Coleman, J. R. I., Gaspar, H. A. *et al.* Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nature genetics* **51**, 1207-1214, doi:10.1038/s41588-019-0439-2 (2019).

44 Demontis, D., Walters, G. B., Athanasiadis, G., Walters, R., Therrien, K., Nielsen, T. T. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. *Nature genetics* **55**, 198-208, doi:10.1038/s41588-022-01285-8 (2023).

45 Martin, J., Walters, R. K., Demontis, D., Mattheisen, M., Lee, S. H., Robinson, E. *et al.* A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. *Biological psychiatry* **83**, 1044-1053, doi:10.1016/j.biopsych.2017.11.026 (2018).

46 Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nature genetics* **51**, 431-444, doi:10.1038/s41588-019-0344-8 (2019).

47 Yu, D., Sul, J. H., Tsetsos, F., Nawaz, M. S., Huang, A. Y., Zelaya, I. *et al.*

Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. *The American journal of psychiatry* **176**, 217-227, doi:10.1176/appi.ajp.2018.18070857 (2019).

48 Hatoum, A. S., Colbert, S. M. C., Johnson, E. C., Huggett, S. B., Deak, J. D., Pathak, G. *et al.* Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. *Nature. Mental health* **1**, 210-223, doi:10.1038/s44220-023-00034-y (2023).

49 Johnson, E. C., Demontis, D., Thorgeirsson, T. E., Walters, R. K., Polimanti, R., Hatoum, A. S. *et al.* A large-scale genome-wide association study meta-analysis of cannabis use disorder. *The lancet. Psychiatry* **7**, 1032-1045, doi:10.1016/s2215-0366(20)30339-4 (2020).

50 Walters, R. K., Polimanti, R., Johnson, E. C., McClintick, J. N., Adams, M. J., Adkins, A. E. *et al.* Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nature neuroscience* **21**, 1656-1669, doi:10.1038/s41593-018-0275-1 (2018).

51 Sanchez-Roige, S., Palmer, A. A., Fontanillas, P., Elson, S. L., Adams, M. J., Howard, D. M. *et al.* Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. *The American journal of psychiatry* **176**, 107-118, doi:10.1176/appi.ajp.2018.18040369 (2019).

52 Lloyd-Jones, L. R., Robinson, M. R., Yang, J. & Visscher, P. M.

Transformation of Summary Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio. *Genetics* **208**, 1397-1408, doi:10.1534/genetics.117.300360 (2018).

53 Bowden, J., Del Greco, M. F., Minelli, C., Davey Smith, G., Sheehan, N. A. & Thompson, J. R. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. *International journal of epidemiology* **45**, 1961-1974, doi:10.1093/ije/dyw220 (2016).

54 Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genetic epidemiology* **37**, 658-665, doi:10.1002/gepi.21758 (2013).

55 Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genetic epidemiology* **40**, 304-314, doi:10.1002/gepi.21965 (2016).

56 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International journal of epidemiology* **44**, 512-525, doi:10.1093/ije/dyv080 (2015).

57 Altman, D. G. & Bland, J. M. Interaction revisited: the difference between two estimates. *BMJ (Clinical research ed.)* **326**, 219,

doi:10.1136/bmj.326.7382.219 (2003).

58 Zuber, V., Grinberg, N. F., Gill, D., Manipur, I., Slob, E. A. W., Patel, A. *et al.* Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. *American journal of human genetics* **109**, 767-782, doi:10.1016/j.ajhg.2022.04.001 (2022).

59 Mansur, R. B., Ahmed, J., Cha, D. S., Woldeyohannes, H. O., Subramaniapillai, M., Lovshin, J. *et al.* Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. *Journal of affective disorders* **207**, 114-120, doi:10.1016/j.jad.2016.09.056 (2017).

60 Mansur, R. B., Zugman, A., Ahmed, J., Cha, D. S., Subramaniapillai, M., Lee, Y. *et al.* Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* **27**, 1153-1162, doi:10.1016/j.euroneuro.2017.08.433 (2017).

61 Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. *Nature reviews. Endocrinology* **19**, 201-216, doi:10.1038/s41574-022-00783-3 (2023).

62 Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J. L. *et al.* Trial of Lixisenatide in Early Parkinson's Disease. *The New*

England journal of medicine **390**, 1176-1185, doi:10.1056/NEJMoa2312323 (2024).

63 McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A. *et al.* Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *The Lancet. Neurology* **23**, 37-45, doi:10.1016/s1474-4422(23)00378-2 (2024).

64 Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., Jr. *et al.* HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. *Molecular psychiatry* **22**, 527-536, doi:10.1038/mp.2016.120 (2017).

65 Belvederi Murri, M., Prestia, D., Mondelli, V., Pariante, C., Patti, S., Olivieri, B. *et al.* The HPA axis in bipolar disorder: Systematic review and meta-analysis. *Psychoneuroendocrinology* **63**, 327-342, doi:10.1016/j.psyneuen.2015.10.014 (2016).

66 Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L. E., Lakshmanan, M. *et al.* Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. *The Lancet. Neurology* **19**, 582-590, doi:10.1016/s1474-4422(20)30173-3 (2020).

67 Zhou, L., Qu, H., Yang, L. & Shou, L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. *BMC endocrine disorders* **23**, 245,

doi:10.1186/s12902-023-01500-5 (2023).

68 Martel, M. M. Sexual selection and sex differences in the prevalence of childhood externalizing and adolescent internalizing disorders. *Psychological bulletin* **139**, 1221-1259, doi:10.1037/a0032247 (2013).

69 Yugar, L. B. T., Sedenho-Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A. M., Sposito, A. C. & Cercato, C. The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis. *Diabetology & metabolic syndrome* **16**, 92, doi:10.1186/s13098-024-01337-5 (2024).

70 MacDonald, P. E., El-Kholy, W., Riedel, M. J., Salapatek, A. M., Light, P. E. & Wheeler, M. B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. *Diabetes* **51 Suppl 3**, S434-442, doi:10.2337/diabetes.51.2007.s434 (2002).

71 Adams, D. M., Reay, W. R., Geaghan, M. P. & Cairns, M. J. Investigation of glycaemic traits in psychiatric disorders using Mendelian randomisation revealed a causal relationship with anorexia nervosa. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* **46**, 1093-1102, doi:10.1038/s41386-020-00847-w (2021).

72 Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L. *et al.* Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ (Clinical*

research ed.) **381**, e074068, doi:10.1136/bmj-2022-074068 (2023).

73 Ye, C. J., Liu, D., Chen, M. L., Kong, L. J., Dou, C., Wang, Y. Y. *et al.* Mendelian randomization evidence for the causal effect of mental well-being on healthy aging. *Nature human behaviour*, doi:10.1038/s41562-024-01905-9 (2024).

74 Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J. & Zhang, J. H. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* **32**, 2201-2210, doi:10.1038/jcbfm.2012.133 (2012).

75 Steinberg, G. R. & Carling, D. AMP-activated protein kinase: the current landscape for drug development. *Nature reviews. Drug discovery* **18**, 527-551, doi:10.1038/s41573-019-0019-2 (2019).



Figure 1. IVW MR estimates for the associations of GLP-1R activation with mental health well-being. BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive associations with the well-being spectrum, life satisfaction, and positive affect and negative associations with neuroticism and depressive

713 symptoms indicate better mental health well-being. Estimates are presented in standard deviation units for mental health well-being per 1-kg/m^2

714 decrease in BMI or per 1-mmol/mol decrease in HbA1c.


(a) BMI lowering
Lower BMI by GLP-1R activation
Lower BMI
(b) HbA1c lowering
Lower HbA1c by GLP-1R activation
Lower HbA1c
Outcome
Case/control
Odds ratio (95% CI)
P value
Depression 170,756/329,443 0.83 (0.74 to 0.94) .003
0.98 (0.97 to 0.99) <.001
Post-partum depression 17,339/53,426 0.62 (0.43 to 0.89) .01
0.98 (0.96 to 1.00) .03
Bipolar disorder 41,917/371,549 0.61 (0.47 to 0.79) <.001
1.00 (0.98 to 1.02) .77
Bipolar disorder I 25,060/449,978 0.58 (0.42 to 0.80) <.001
1.01 (0.98 to 1.03) .57
Bipolar disorder II 6,781/364,075 0.56 (0.32 to 0.97) .04
1.00 (0.97 to 1.03) .94
PTSD 23,212/151,447 0.71 (0.47 to 1.07) .10
0.94 (0.92 to 0.96) <.001
Schizophrenia 53,386/77,258 0.88 (0.69 to 1.11) .28
1.03 (1.01 to 1.05) .01
Anorexia nervosa 16,992/55,525 0.95 (0.65 to 1.39) .79
1.10 (1.07 to 1.12) <.001
ADHD 38,691/186,843 0.72 (0.55 to 0.94) .01
0.89 (0.87 to 0.90) <.001
Autism spectrum disorder 18,381/27,969 0.69 (0.47 to 1.02) .06
0.98 (0.95 to 1.00) .05
Tourette syndrome 4,819/9,488 1.27 (0.62 to 2.59) .52
0.97 (0.93 to 1.01) .14
0.4 0.6 1.0 1.6 2.7
Odds ratio (95% CI)
P value
1.03 (0.94 to 1.13) .54
1.00 (1.00 to 1.00) .90
0.83 (0.61 to 1.14) .25
1.00 (0.99 to 1.01) .41
1.19 (0.97 to 1.46) .09
1.01 (0.99 to 1.02) .34
1.18 (0.92 to 1.53) .20
1.01 (1.00 to 1.02) .25
1.47 (0.93 to 2.33) .10
1.00 (0.99 to 1.02) .86
1.24 (0.88 to 1.74) .22
1.00 (0.99 to 1.01) .64
1.13 (0.93 to 1.37) .21
1.00 (0.99 to 1.01) .45
1.53 (1.13 to 2.09) .007
1.02 (1.00 to 1.03) .02
0.89 (0.73 to 1.09) .27
0.99 (0.98 to 1.00) .02
0.75 (0.55 to 1.03) .07
1.00 (0.99 to 1.02) .43
0.54 (0.31 to 0.94) .03
0.99 (0.97 to 1.01) .18
0.4 0.6 1.0 1.6 2.7

716 Figure 2. IVW MR estimates for the associations of GLP-1R activation with the risk of mental health disorders.

717 ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

718 hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization; PTSD, post-traumatic stress disorder. Black squares denote

719 genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically

720 predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Estimates are presented as odds ratio per 1-kg/m^2 decrease in BMI

721 or per 1-mmol/mol decrease in HbA1c.

722



Figure 3. IVW MR estimates for the associations of GLP-1R activation with the risk of substance use disorders and AUDIT scores. AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c

based on genome-wide variants. Positive associations with AUDIT scores indicate higher risk of alcohol use disorders. Estimates are presented in standard deviation unit for substance use disorder risk, as logodds for cannabis use disorder and alcohol dependence, and as log10 transformed score for AUDIT scores per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.

(a) Well-being spectrum
Probability for colocalization 59.3%
Conditional probability 84.0%
(b) Life satisfaction
Probability for colocalization 73.8%
Conditional probability 85.2%
(c) Positive affect
Probability for colocalization 68.1%
Conditional probability 82.9%
(d) Neuroticism
Probability for colocalization 61.1%
Conditional probability 80.9%
(e) Depressive symptoms
Probability for colocalization 62.7%
Conditional probability 82.8%
(f) Depression
Probability for colocalization 3.8%
Conditional probability 31.3%
(g) Bipolar disorder
Probability for colocalization 45.9%
Conditional probability 91.8%
(h) Bipolar disorder I
Probability for colocalization 34.7%
Conditional probability 88.5%
rs4714290
rs847784
rs17757975
BMI
Well-being
Life satisfaction
Positive affect
Neuroticism
Depressive symptoms
Depression
Bipolar disorder
Bipolar disorder I
-log10(pval)
Position (chr6)
38000000 38500000 39000000 39500000 40000000

732

Figure 4. Colocalization analyses for BMI and each significant outcome at the *GLP1R* gene.

BMI, body mass index. Probability for colocalization means the posterior probability of a shared variant associated with both traits; conditional probability means the posterior probability of a shared variant associated with both traits conditional on the presence of a variant associated with the outcome. Conditioning on the presence of a shared variant associated with both traits, the variant highlighted with a label had the largest probability of being the shared variant.